{"id":5814,"date":"2025-11-27T16:11:03","date_gmt":"2025-11-27T23:11:03","guid":{"rendered":"https:\/\/allphasepharma.com\/dir\/?p=5814"},"modified":"2025-12-04T17:13:35","modified_gmt":"2025-12-05T00:13:35","slug":"obeldesivir-fails-in-yet-another-study","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2025\/11\/27\/5814\/obeldesivir-fails-in-yet-another-study\/","title":{"rendered":"Obeldesivir Fails in Yet Another Study"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

There are studies that are bound to succeed, and those that are likely to fail.  A failed trial is nothing to be proud of \u2013 and in this case, it was a gamble against overwhelming odds.  We feel the Gilead marketing department was pushing their luck big time with this trial.[1]<\/a><\/p>\n\n\n\n

Maybe we should be glad the trial failed; otherwise, we would have another Tamiflu situation, 1 day improvement in symptom relief at best, being touted as clinically important.  For obeldesivir, an oral version of remdesivir, we would have expected a remdesivir-like study, trying to mimick past successes with a drug that has a different PK and more favorable metabolic features but the same MoA.<\/p>\n\n\n\n

Not here. The OAKTREE study was more or less an early intervention trial with the assumption that early neutralization of Covid-19 might somehow be of clinical benefit, be it by reducing the duration of symptomatic disease or by reducing the frequency of other bad outcomes, such as hospitalization and death. This rationale is not wrong, but one would presumably first test this hypothesis in a population at high risk for disease progression, as in the elderly, immunocompromised, or patients with underlying diseases who cannot deal well with Covid-19 infection. Once proven effective in this population, it would make sense to take the next step…<\/p>\n\n\n\n

Well, the opposite was done here, namely, obeldesivir was tested in a population at very low risk of progression, in newly infected young adults (median age = 41 years!) without immune compromise or comorbidities.  Most had a history of prior infection or vaccination. This is not the population for which remdesivir had shown benefit in the past and been approved.  <\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

However, this premise was not altogether wrong, as this table showed; earlier intervention was associated with earlier resolution of symptoms. In this regard, obeldesivir was clearly superior to placebo. Just not enough to make it clinically relevant.<\/p>\n\n\n\n

If this were a timed exposure study of volunteers to the virus, with a fixed nasal inoculum at time zero, followed by drug administration after 8, 24, 48, and 72 hrs, we might have seen a treatment effect on symptom relief, and maybe even a dose response.  However, this would be a PoC trial, not reflecting the real world situation. The way the study was designed though, in the presence of preexisting immunity, the envelope was pushed too far.<\/p>\n\n\n\n

Of course, Gilead knew that and wisely embarked on another Phase 3 tree trial which they called BIRCH. This one was in patients with risk factors for severe Covid-19 infections, a more appropriate target population; the endpoints were COVID-19\u2013related hospitalization or all-cause death.  Too bad this study had to be stopped prematurely, because actual hospitalization rates were much lower than anticipated, almost zero in either arm.  Hence, efficacy for obeldesivir could not be established. <\/p>\n\n\n

\u201cUltimately, the mild clinical course and rapid recovery seen in this study, which is representative of the current COVID-19 landscape in non-hospitalised adults without risk factors for progression to severe disease might have impeded demonstration of a significant and clinically meaningful treatment benefit with regard to time to symptom alleviation or resolution\u201d<\/span>1<\/sup><\/em><\/p>\n<\/div>\n\n\n\n

Unfortunately, neither BIRCH nor OAKTREE achieved its stated objectives. According to the authors, it may have been vaccination that protected patients, obliterating any significant contribution of the antiviral drug.[2]<\/a>  We agree with this assessment wholeheartedly.<\/p>\n\n\n\n

Just as a reminder:  Remdesivir was approved in the early days of the Covid-19 epidemic based on data generated in non-immune, unvaccinated patients.  It was never considered to be a particularly potent anti-Covid drug; it still only plays a secondary role in the latest Covid treatment guidelines (see below). We are not so sure it deserves to be on the list at all, as we are now in the post-vaccine era and dealing with patients that have at least partial immunity.<\/p>\n\n\n\n

\n

Of course, the same holds true for molnupiravir, another nucleoside drug approved based on study results in unvaccinated patients<\/span><\/p>\n<\/blockquote>\n\n\n\n

<\/p>\n\n\n\n

Gilead is clearly a company committed to nucs and nuc research; having developed remdesivir in-house, there was a strong drive to push development of an oral version.  We believe that obeldesivir would not have failed in the early Covid days; it would have received Emergency Use Authorization (EUA) and been approved.<\/p>\n\n\n\n

Where does all this leave obeldesivir?  A recent Gilead press release informs us that obeldesivir studies in RSV infection have been stopped for lack of clinically relevant benefit.  It seems obeldesivir is on its way out.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

Maybe not surprisingly, Gilead presentations at ID Week last month were not centered on obeldesivir but rather on lenacapavir, their great new HIV drug, a powerful long-acting therapeutic both for prevention and treatment.  Lenacapavir is a game changer for HIV, just as Sovaldi was for HCV.  It is also a product of Gilead research but not a nucleoside, sorry to say!<\/p>\n\n\n\n

Actually, we find it quite amazing that the nucleoside class of drugs is still being worked on, still producing NCEs worthy of development.  AZT was a nucleoside making it into the clinic as the first anti-HIV, developed by BMS. John Martin recognized the value of tenofovir, a nucleotide, and started his own company, Gilead, as he left BMS.  Gilead then bought sofosbuvir, a nucleoside drug from Pharmasset, which for the first time was able to cure HCV infection. Gilead has done very well managing its nucleoside franchise by combining drugs in the HIV and HCV portfolios to further improve viral load suppression and clinical efficacy. <\/p>\n\n\n\n

Lenacapavir will add a new non-nuc chapter.<\/p>\n\n\n\n

\n\n\n\n

REFERENCES
<\/strong>[1]<\/a> Ogbuago O.  Efficacy and safety of obeldesivir in low-risk, nonhospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.  Lancet Infect Dis 2025, 25: 1282
[2]<\/a> Steichu-Cercel A.  Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With Coronavirus Disease 2019.  (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study.  https:\/\/doi.org\/10.1093\/cid\/ciaf406<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

There are studies that are bound to succeed, and those that are likely to fail.  A failed trial is nothing to be proud of \u2013 and in this case, it was a gamble against overwhelming odds.  We feel the Gilead marketing department was pushing their luck big time with this Continue reading Obeldesivir Fails in Yet Another Study<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":5826,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[227,3,18],"tags":[1271,403,2547,2550,796,2541,126,1583,24,49,2545,2548,2542,2540,2549,2543,2544,25,2546,2551],"class_list":["post-5814","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_news","category-the_viewpoint","tag-allphase-pharma-consulting","tag-antibiotic-blog","tag-azt","tag-birch-study","tag-bms","tag-covid-19-therapeutics","tag-gilead","tag-harald-reinhart","tag-hcv","tag-hiv","tag-idsa-covid-guideline","tag-lenacapavir","tag-molnupiravir","tag-nucleoside-antivirals","tag-oaktree-study","tag-obeldesivir","tag-remdesivir","tag-sofosbuvir","tag-vaccination-impact","tag-veklury"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/Obeldesivir-slider.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-1vM","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":771,"url":"https:\/\/allphasepharma.com\/dir\/2014\/08\/28\/771\/following-the-publication-trail-of-two-rsv-drugs\/","url_meta":{"origin":5814,"position":0},"title":"Following The Publication Trail of Two RSV Drugs","author":"Harald","date":"August 28, 2014","format":false,"excerpt":"In a publication from 2007, investigators from Arrow Pharmaceuticals told us that A-60444 (later renamed to\u00a0RSV-604) was already in Phase 2.\u00a0 Since then, it has been very quiet about this compound.\u00a0 Some have suggested that Novartis has stopped development [1], an impression supported by the fact that the drug is\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"RSV from Ref. [6]","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/08\/rsv.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":2157,"url":"https:\/\/allphasepharma.com\/dir\/2015\/12\/03\/2157\/there-is-momentum-building-for-rsv-therapeutics\/","url_meta":{"origin":5814,"position":1},"title":"There is Momentum Building for RSV Therapeutics","author":"Harald","date":"December 3, 2015","format":false,"excerpt":"Sometimes \u2013 for no obvious reason \u2013 there is a flurry of publications from a particular area which has been quiet for a long time.\u00a0 RSV is such an area where new drug development had a hard time getting started.\u00a0 There was always the lure of big money: an infection\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"RSV - banner copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/11\/RSV-banner-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/11\/RSV-banner-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/11\/RSV-banner-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1590,"url":"https:\/\/allphasepharma.com\/dir\/2015\/06\/22\/1590\/tenofovir-bmd-and-monitoring-of-renal-function\/","url_meta":{"origin":5814,"position":2},"title":"Tenofovir, BMD and Monitoring of Renal Function","author":"Harald","date":"June 22, 2015","format":false,"excerpt":"The approved tenofovir \/ Viread label lists not only standard\u00a0nucleoside-class side effects but also\u00a0\u2013 since an update in 2012 \u2013 makes mention of diminished bone mineral density (BMD) in the Warnings \/ Precautions section. Demonstrating that a particular drug affects BMD in patients who are already at an increased risk\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"BMD TDF","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/06\/BMD-TDF.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":2328,"url":"https:\/\/allphasepharma.com\/dir\/2016\/02\/26\/2328\/brincidofovir-another-drug-fails-in-phase-3\/","url_meta":{"origin":5814,"position":3},"title":"Brincidofovir \u2013 Another Drug Fails in Phase 3","author":"Harald","date":"February 26, 2016","format":false,"excerpt":"It is sad to see a pivotal trial fail, and you have to wonder why we recently had several such late-stage \u2018mishaps\u2019. Take Tetraphase\u2019s eravacycline which failed in a Phase 3 cUTI trial. We have analyzed this drug's failure in\u00a0earlier blogs; there is reason to believe that inadequate dosing was\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"Chimerix - slider copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Chimerix-slider-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Chimerix-slider-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Chimerix-slider-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1958,"url":"https:\/\/allphasepharma.com\/dir\/2015\/09\/24\/1958\/after-icaac-some-more-thoughts-on-eravacycline-in-cuti-and-ignite-2\/","url_meta":{"origin":5814,"position":4},"title":"After ICAAC: Some More Thoughts on Eravacycline in cUTI and IGNITE-2","author":"Harald","date":"September 24, 2015","format":false,"excerpt":"When a well-designed pivotal Phase 3 trial fails to show NI, it demands an explanation.\u00a0 While awaiting the company\u2019s analysis of the data, many possible explanations are bandied about.\u00a0 So it was not surprising that the eravacycline cUTI study (IGNITE-2) was mentioned quite often during ICAAC 2015, in sessions and\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"Erava2blog copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/Erava2blog-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/Erava2blog-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/Erava2blog-copy.jpg?resize=525%2C300 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/Erava2blog-copy.jpg?resize=700%2C400 2x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/Erava2blog-copy.jpg?resize=1050%2C600 3x"},"classes":[]},{"id":313,"url":"https:\/\/allphasepharma.com\/dir\/2014\/06\/18\/313\/snapshot-hcv-drugs-in-development\/","url_meta":{"origin":5814,"position":5},"title":"Snapshot: HCV Drugs in Development","author":"Harald","date":"June 18, 2014","format":false,"excerpt":"It's becoming a daunting task to follow the field given the rapid-fire release of study results and the many recent submissions of new direct-acting antiviral (DAA) drugs. All will be given as cocktails, with or without interferon or ribavirin, and for various durations\u00a0depending on genotype (GT) and other factors. \u00a0How\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/5814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=5814"}],"version-history":[{"count":20,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/5814\/revisions"}],"predecessor-version":[{"id":5898,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/5814\/revisions\/5898"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/5826"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=5814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=5814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=5814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}